Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of clonazolam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
Clonazolam is considered extremely psychologically addictive with high abuse potential. Compulsive redosing is commonly reported, and the substance is noted for producing euphoria more frequently than many other benzodiazepines, which may increase its reinforcing properties. Rebound anxiety following use can facilitate cycles of dependence.
Physical dependence can develop within days of regular use, and in some cases even after a single large dose. Withdrawal is potentially life-threatening and may include anxiety, insomnia, cognitive impairment, elevated blood pressure, increased heart rate, tremor, restlessness, and in severe cases psychosis and seizures. Abrupt discontinuation is strongly discouraged; gradual tapering under medical supervision is recommended.
Clonazolam has relatively low acute toxicity when used alone, and most benzodiazepine-only overdoses are not fatal. However, the substance becomes potentially lethal when combined with other depressants such as alcohol, opioids, or barbiturates. No specific lethal dose has been established in humans. Overdose symptoms include severe respiratory depression, loss of consciousness, and confusion.
Psychosis is rare during intoxication but may occur during severe benzodiazepine withdrawal. Paradoxical reactions including aggression, violent behavior, and increased anxiety occur with an incidence below 1% in the general population but are more frequent in recreational abusers, individuals with mental disorders, and those on high-dose regimens.
Clonazolam possesses anticonvulsant properties during active use. However, abrupt discontinuation after regular use poses a significant seizure risk that can be life-threatening. Gradual tapering is essential for anyone who has developed physical dependence.
Clonazolam was first synthesized in 1971 by The Upjohn Company, the pharmaceutical corporation that would later bring alprazolam (Xanax) to market. In the original research, the compound was described as the most active substance in the series of triazolobenzodiazepines tested. Despite this notable…
Classified as a Schedule 9 prohibited substance under federal law. Substances in this category are considered to have no recognized therapeutic value and high potential for misuse.
Controlled under § 1, d), 2. of Nařízení vlády č. 463/2013 Sb. Use is restricted exclusively to limited research purposes or very limited therapeutic applications.
Regulated under the Pharmaceutical Affairs Law. Possession and sale are illegal without authorization.
Classified as a New Psychoactive Substance under Polish drug legislation. Possession and distribution are prohibited.
Classified as an addictive substance following a recommendation by Sweden's public health agency on June 1, 2015. Production, import, trading, and possession require special authorization.
Classified as a Class C drug under the May 2017 amendment to the Misuse of Drugs Act 1971, alongside several other designer benzodiazepines. Possession, production, and supply are criminal offenses.
Listed under Schedule 4 of the Controlled Drugs and Substances Act, restricting possession and distribution without authorization.
Controlled under the Betäubungsmittelgesetz (Narcotics Act) since November 11, 2021. Production and import with intent to distribute, administration to another person, possession, and trading are prohibited.
Controlled as a List 2 substance under the Opium Law. Possession, production, and distribution are illegal.
Listed as a Schedule III controlled substance since 2017. Subject to restrictions on production, distribution, and possession.
Specifically named as a controlled substance under Verzeichnis E (List E) of Swiss narcotics legislation.
Temporarily placed under Schedule I of the Controlled Substances Act effective July 26, 2023, following DEA consideration announced in December 2022. The temporary scheduling has been extended until July 26, 2026. Not FDA approved for human consumption. Several states enacted their own scheduling prior to federal action, including Virginia, Oregon, and Minnesota (since August 2020).
